scholarly journals COVID-19 model-based practice changes in managing a large prostate cancer practice: following the trends during a month-long ordeal

2020 ◽  
Author(s):  
Kulthe Ramesh Seetharam Bhat ◽  
Marcio Covas Moschovas ◽  
Travis Rogers ◽  
Fikret F. Onol ◽  
Cathy Corder ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Model Based ◽  
Large Prostate

1962: Correlation between Prostate Cancer Detection Rate and Gland Volume: Is Increased Biopsy Sampling Needed for Patients with a Large Prostate?

2007 ◽  
Vol 177 (4S) ◽  
pp. 651-651
Author(s):  
Nicolas B. Delongchamps ◽  
Vishal Chandan ◽  
Richard Jones ◽  
Gregory Threatte ◽  
Mary Jumbelic ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Detection Rate ◽  
Cancer Detection Rate ◽  
Prostate Cancer Detection ◽  
Gland Volume ◽  
Large Prostate

On the pre-clinical validation of a commercial model-based optimisation engine: Application to volumetric modulated arc therapy for patients with lung or prostate cancer

2014 ◽  
Vol 113 (3) ◽  
pp. 385-391 ◽  
Author(s):  
Antonella Fogliata ◽  
Francesca Belosi ◽  
Alessandro Clivio ◽  
Piera Navarria ◽  
Giorgia Nicolini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Volumetric Modulated Arc Therapy ◽  
Clinical Validation ◽  
Model Based ◽  
Arc Therapy

Diffusion-weighted imaging of prostate cancer using a statistical model based on the gamma distribution

2014 ◽  
Vol 42 (1) ◽  
pp. 56-62 ◽  
Author(s):  
Hiroshi Shinmoto ◽  
Koichi Oshio ◽  
Chiharu Tamura ◽  
Shigeyoshi Soga ◽  
Teppei Okamura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Statistical Model ◽  
Gamma Distribution ◽  
Diffusion Weighted Imaging ◽  
Model Based ◽  
Diffusion Weighted

404 DEVELOPMENT OF MULTIPARAMETRIC PROGNOSTIC MODELS USING LARGE PROSTATE CANCER TISSUE MICROARRAYS

2011 ◽  
Vol 10 (2) ◽  
pp. 141
Author(s):  
S. Minner ◽  
M.C. Tsourlakis ◽  
J. Müller ◽  
L. Burkhardt ◽  
P. Tennstedt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tissue Microarrays ◽  
Prognostic Models ◽  
Cancer Tissue ◽  
Prostate Cancer Tissue ◽  
Large Prostate

Model-Based Cost-Effectiveness Analyses for Prostate Cancer Chemoprevention

2013 ◽  
Vol 31 (4) ◽  
pp. 289-304 ◽  
Author(s):  
Stephanie R. Earnshaw ◽  
Andrew P. Brogan ◽  
Cheryl L. McDade
Keyword(s):  
Prostate Cancer ◽  
Cost Effectiveness ◽  
Cancer Chemoprevention ◽  
Model Based

Prostate cancer risk assessment model: a scoring model based on the Swedish Family-Cancer Database

2012 ◽  
Vol 49 (5) ◽  
pp. 345-352 ◽  
Author(s):  
Hassan Roudgari ◽  
Kari Hemminki ◽  
Andreas Brandt ◽  
Jan Sundquist ◽  
Mahdi Fallah
Keyword(s):  
Prostate Cancer ◽  
Risk Assessment ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Assessment Model ◽  
Cancer Risk Assessment ◽  
Risk Assessment Model ◽  
Scoring Model ◽  
Model Based ◽  
Swedish Family

Prevention of hip fractures in older men receiving androgen deprivation therapy for prostate cancer: A cost-effectiveness analysis

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6530-6530
Author(s):  
K. Ito ◽  
E. Elkin ◽  
M. Morris
Keyword(s):  
Prostate Cancer ◽  
Cost Effectiveness ◽  
Androgen Deprivation Therapy ◽  
Hip Fractures ◽  
Androgen Deprivation ◽  
Mineral Density ◽  
T Score ◽  
Model Based ◽  
Screening Cost ◽  
The Impact

6530 Background: Androgen deprivation therapy (ADT) increases the risk of osteoporotic fractures. Our goal was to assess the cost-effectiveness of bone mineral density (BMD) screening followed by alendronate therapy at the onset of ADT in men with T2c-T4N0 prostate cancer. Methods: We developed a Markov model of prostate cancer progression and simulated the experience of 70-year-old men with T2c-T4N0 prostate cancer starting a 2-year course of ADT after radiation therapy. We compared four strategies: No BMD screening and no alendronate therapy; BMD screening with alendronate therapy for men with osteoporosis (a T-score ≤ -2.5); BMD screening with alendronate therapy for men with osteoporosis or osteopenia (a T-score ≤ -1.0); and universal alendronate therapy without BMD screening. The main outcome measure was cost per quality-adjusted life year (QALY) gained. Data sources were U.S. epidemiological studies and health care cost figures. A model-based estimate of median survival was 9.5 years. Proportions of men who had a T-score ≤ -2.5 and -1.0 were 10% and 45%, respectively. A model-based incidence of hip fractures with no therapy was 0.93 per 100 person-years. Alendronate reduced the risk of hip fractures by 10%. Results: Compared with no screening and no therapy, BMD screening with alendronate therapy for men with osteopenia or osteoporosis cost $66,100 per QALY gained. BMD screening with alendronate therapy only for those with osteoporosis was slightly more costly and more effective, but had a less favorable ICER. Universal alendronate therapy without screening cost $1,580,300 per QALY gained. These results were most sensitive to assumptions about the impact of alendronate on the rate of BMD loss during ADT and the price of alendronate. Conclusions: In men with T2c-T4N0 prostate cancer, BMD screening with alendronate therapy for men with osteoporosis or osteopenia is a cost-effective use of resources, compared with other medical interventions in oncology. [Table: see text] No significant financial relationships to disclose.

Detection of  prostate cancer with histoscanning: A retrospective analysis in 85 patients.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 53-53
Author(s):  
Robin Epplen ◽  
Julius van Essen ◽  
Thomas van Erps ◽  
Daniel Porres ◽  
David J. K. P. Pfister ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Statistical Significance ◽  
Transrectal Ultrasound ◽  
Three Dimensional ◽  
Solid Organ ◽  
High Detection Rate ◽  
Prostate Cancers ◽  
Large Prostate ◽  
Program Data

53 Background: HistoScanning is a tissue differentiation and visualization tool which identifies changes to solid organ tissues. It uses a specific three dimensional transrectal ultrasound device to acquire and transmit data to a software program. Data is processed and suspicious areas in the prostate are projected in 3D. Our objective was to compare HistoScanning with histopathology of radical prostatectomy specimens and to determine sensitivity regarding the detection of cancer volume and localization. Methods: We analyzed the preoperative results of histoscanning in 85 men underwent radical prostatectomy. All prostatectomy specimens were processed according to the Stanford protocol by an experienced uro-pathologist.Results were correlated with final pathology according to localisation and volume. A match was defined as a HistoScan positive lesion in a correspondent histopathologically positive area.Results were analyzed according to pT-stadium, GS, PSA, cancerous tissue volume and volume of HistoScanning-lesions. Results: Mean patients’ age was 62,8 yrs, PSA 11.83ng/ml, prostate volume was 47,5 ml and mean tumor volume was 4,80ml. 44 patients had a pT2 tumor, 38 had a pT3 carcinoma (3 pts pT4). 8 pts had salvage prostatectomy. 9 patients had GS of 6,50 and 18 pts had GS 7 and GS ≥8 respectively. HistoScanning had 74% overall sensitivity.Sensitivity was higher for pT3 tumors (92%) than for pT2 carcinoma (61,36%). HistoScanning detected (5/9=55%) of GS 6, (37/50= 74%) of GS 7 and 15/18=83% of GS ≥8 carcinoma. Preoperative PSA had no statistical significance. HistoScanning detected small tumors (<1 ml) in 50%, intermediate (1-5ml) in 57,5% and large(>5ml) in 86% respectively. Identical results are seen regarding the volume of suspicious lesions. For small (≤0,5 ml), intermediate (0,5-2ml) and large (>2ml) lesions, it correctly predicted prostate cancer localisatio 33%, 78,5% and 64,7%, respectively. Conclusions: HistoScanning seems to have a great potential in the detection of significant prostate cancer. In particular, extracapsular, poor differentiated and large prostate cancers show a high detection rate. However, larger prospective studies are needed to verify these preliminary results.

Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings

Urology ◽  
2006 ◽  
Vol 68 (4) ◽  
pp. 815-819 ◽  
Author(s):  
Masahiko Inahara ◽  
Hiroyoshi Suzuki ◽  
Satoko Kojima ◽  
Akira Komiya ◽  
Satoshi Fukasawa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Core Biopsy ◽  
Digital Rectal Examination ◽  
Prostate Cancer Detection ◽  
Rectal Examination ◽  
Large Prostate
Sign in / Sign up

Export Citation Format

Share Document